We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Attorney General Keith Ellison announced a settlement with Novo Nordisk that let's Minnesotans buy its insulin products for ...

The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.

A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir, arguing that it could leave some diabetics without an ...

The approval covers all 27 European Union member states. Tresiba (insulin degludec) is a once-daily new-generation based insulin analogue with an ultra-long duration of action. Ryzodeg (insulin ...

Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

Minnesota Attorney General Keith Ellison on Monday announced a settlement in a lawsuit against insulin manufacturer Novo Nordisk. Minnesota residents will now be able to get Novo Nordisk insulin ...

Many drugs, including insulin, essentially became free. But the American Rescue Plan made a major change that hit drug companies with even larger penalties for raising prices. In January 2024 ...

Novo Nordisk (NYSE:NVO) is a Denmark-based firm that owns drug brands such as Levemir, Tresiba, NovoLog, Novolin R, and Novolin N. Overall, NVO ranks 6th on our list of firms that took a hit on ...